0000000000644883

AUTHOR

A. Paradiso

showing 2 related works from this author

High prevalence of fragility vertebral fractures in patients hospitalised in Internal Medicine Units. Results of the POINT (Prevalence of Osteoporosi…

2015

Abstract Background Osteoporotic vertebral fractures (VFs) often go unrecognised in both healthy individuals and in pathological conditions. Few data exist on VFs in patients hospitalised in Internal Medicine Units (IMUs), who often suffer from multiple concomitant chronic disorders. Aim of the study This multicentre cross-sectional study was aimed at assessing the prevalence of VFs in an unselected population of patients referring to IMUs. Correlations between VFs and the main coexisting diseases were also investigated. Methods Information on demographic, clinical and laboratory findings, and on the presence of known risk factors for osteoporosis was recorded. The Genant's semi-quantitativ…

Malemedicine.medical_specialtyHistologyPhysiologyEndocrinology Diabetes and MetabolismOsteoporosisPrevalenceVery frequentEndocrinologyInternal medicineInternal MedicinePrevalenceMedicineHumansIn patientvertebral fracturesPathologicalAgedDemographybusiness.industryMiddle Agedmedicine.diseaseComorbidityinternal medicine; osteoporosis; vertebral fracturesosteoporosisSpineHospitalizationDiabetes and Metabolisminternal medicineLogistic ModelsConcomitantVertebral fracturesCohortMultivariate AnalysisOsteoporosis vertebral fractures Genant's semi-quantitative methodOsteoporosisSpinal FracturesFemaleInternal medicine; Osteoporosis; Vertebral fractures; Aged; Demography; Female; Hospitalization; Humans; Internal Medicine; Logistic Models; Male; Middle Aged; Multivariate Analysis; Osteoporosis; Prevalence; Spinal Fractures; Spine; Endocrinology Diabetes and Metabolism; Histology; Physiologybusiness
researchProduct

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as …

2005

The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A …

AdultCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsDisease-Free SurvivalDrug Administration Schedulebreast cancerchemoendocrine treatmentAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineAdjuvant therapyHumansDoxorubicinCyclophosphamideanthracyclinesGynecologyChemotherapypremenopausalbusiness.industryGoserelinadjuvant therapyMiddle AgedCombined Modality TherapyTamoxifenRegimenMethotrexateOncologyChemotherapy AdjuvantDoxorubicinFluorouracilLymphatic MetastasisGoserelinFemaleFluorouracilbusinessTamoxifenFollow-Up Studiesmedicine.drugBritish Journal of Cancer
researchProduct